Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results
  • Duloxetine: marketed as Cymbalta▼ and Yentreve▼ for different disorders

    Patients should be assessed regularly due to reported cases of suicidal ideation and suicidal behaviour during treatment with duloxetine or shortly after stopping treatment.

    • Therapeutic area: Endocrinology, diabetology and metabolism and 2 others
    • Published:
  • Pregabalin (Lyrica): findings of safety study on risks during pregnancy

    A new study has suggested pregabalin may slightly increase the risk of major congenital malformations if used in pregnancy. Patients should continue to use effective contraception during treatment and avoid use in pregnancy …

    • Therapeutic area: Dispensing GP practices and 3 others
    • Published: